NCT05921760: An ongoing trial by Servier Bio-Innovation LLC
This trial is ongoing. It must report results 3 weeks, 3 days ago.
Full data
| Full entry on ClinicalTrials.gov | NCT05921760 |
|---|---|
| Title | A Phase 1/2, Safety Lead-in and Dose Expansion, Open-label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Activity of Ivosidenib in Combination With Nivolumab and Ipilimumab in Previously Treated Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 23, 2023 |
| Completion date | Nov. 21, 2024 |
| Required reporting date | Nov. 21, 2025, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |